Works matching DE "MONOCLONAL antibodies"
Results: 5000
The Anti‐Human P2X7 Monoclonal Antibody (Clone L4) Can Mediate Complement‐Dependent Cytotoxicity of Human Leukocytes.
- Published in:
- European Journal of Immunology, 2025, v. 55, n. 1, p. 1, doi. 10.1002/eji.202451196
- By:
- Publication type:
- Article
Development of a Colloidal Gold Immunochromatographic Strip for Specific Detection of Photobacterium damselae subsp. piscicida.
- Published in:
- Journal of Fish Diseases, 2025, v. 48, n. 3, p. 1, doi. 10.1111/jfd.14062
- By:
- Publication type:
- Article
Japanese Phase 1 Study for Global Development of Anti‐TL1A Antibody PF‐06480605: A Randomized, Placebo‐Controlled, Single‐Ascending Dose Study.
- Published in:
- CTS: Clinical & Translational Science, 2025, v. 18, n. 3, p. 1, doi. 10.1111/cts.70187
- By:
- Publication type:
- Article
Advances in the management of high‐risk localised muscle invasive bladder cancer.
- Published in:
- BJU International, 2025, v. 135, n. 3, p. 364, doi. 10.1111/bju.16672
- Publication type:
- Article
Prevalence and Spectrum of Neuropathies in a Cohort of 585 Patients With Immunoglobulin A Monoclonal Gammopathy.
- Published in:
- European Journal of Neurology, 2025, v. 32, n. 2, p. 1, doi. 10.1111/ene.70087
- By:
- Publication type:
- Article
Switching from natalizumab to antiCD20 monoclonal antibodies: Short transition interval is associated with improved outcome.
- Published in:
- European Journal of Neurology, 2025, v. 32, n. 1, p. 1, doi. 10.1111/ene.16587
- By:
- Publication type:
- Article
Switching from ligand to receptor anti‐calcitonin gene‐related peptide (CGRP) antibodies or vice versa in non‐responders: A controlled cohort study.
- Published in:
- European Journal of Neurology, 2025, v. 32, n. 1, p. 1, doi. 10.1111/ene.16542
- By:
- Publication type:
- Article
Long-term efficacy and safety of secukinumab in patients with moderate-to-severe hidradenitis suppurativa: week 104 results from the SUNSHINE and SUNRISE extension trial.
- Published in:
- British Journal of Dermatology, 2025, v. 192, n. 4, p. 629, doi. 10.1093/bjd/ljae469
- By:
- Publication type:
- Article
The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples.
- Published in:
- British Journal of Dermatology, 2025, v. 192, n. 4, p. 660, doi. 10.1093/bjd/ljae442
- By:
- Publication type:
- Article
Long-term management of moderate-to-severe atopic dermatitis with lebrikizumab and concomitant topical corticosteroids: a 68-week randomized double-blind placebo-controlled phase III trial in Japan (ADhere-J).
- Published in:
- British Journal of Dermatology, 2025, v. 192, n. 4, p. 597, doi. 10.1093/bjd/ljae394
- By:
- Publication type:
- Article
A new algorithm for coeliac disease based on the 'long forgotten' TCRγδ<sup>+</sup> intra‐epithelial lymphocytes detected with an antibody working on FFPE sections.
- Published in:
- Histopathology, 2025, v. 86, n. 3, p. 397, doi. 10.1111/his.15330
- By:
- Publication type:
- Article
Correction to "Disseminated intravascular coagulation is an underestimated but fatal adverse event associated with blinatumomab therapy: A pharmacovigilance analysis of FAERS".
- Published in:
- International Journal of Cancer, 2025, v. 156, n. 9, p. E7, doi. 10.1002/ijc.35367
- Publication type:
- Article
Effects of fremanezumab on migraine‐associated symptoms and medication use in Japanese and Korean patients with episodic migraine: Exploratory endpoint analysis of a multicenter, randomized, double‐blind, placebo‐controlled trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2025, v. 65, n. 3, p. 399, doi. 10.1111/head.14810
- By:
- Publication type:
- Article
Pharmacological differences and switching among anti‐CGRP monoclonal antibodies: A narrative review.
- Published in:
- Headache: The Journal of Head & Face Pain, 2025, v. 65, n. 2, p. 342, doi. 10.1111/head.14903
- By:
- Publication type:
- Article
Erenumab in a patient with persistent headaches after subarachnoid hemorrhage: A case report of an effective treatment.
- Published in:
- Headache: The Journal of Head & Face Pain, 2025, v. 65, n. 2, p. 373, doi. 10.1111/head.14884
- By:
- Publication type:
- Article
Long‐term reductions in acute headache medication use after eptinezumab treatment in patients with migraine and prior preventive treatment failures: Post hoc analysis of the DELIVER randomized trial.
- Published in:
- Headache: The Journal of Head & Face Pain, 2025, v. 65, n. 1, p. 101, doi. 10.1111/head.14862
- By:
- Publication type:
- Article
Impact of Biologics on Surgery in Chronic Rhinosinusitis with Polyps and Allergic Fungal Sinusitis.
- Published in:
- Laryngoscope, 2025, v. 135, n. 2, p. 593, doi. 10.1002/lary.31774
- By:
- Publication type:
- Article
The Impact of Monoclonal Antibody Usage on Hearing Outcomes: A Systematic Review.
- Published in:
- Laryngoscope, 2025, v. 135, n. 2, p. 491, doi. 10.1002/lary.31763
- By:
- Publication type:
- Article
GD2-targeted theranostics of neuroblastoma with [<sup>64</sup>Cu]Cu/[<sup>177</sup>Lu]Lu-hu3F8.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2025, v. 52, n. 5, p. 1764, doi. 10.1007/s00259-024-07033-w
- By:
- Publication type:
- Article
Preclinical evaluation of 64Cu/177Lu-labelled anti-CD30 monoclonal antibody for theranostics in CD30-positive lymphoma.
- Published in:
- European Journal of Nuclear Medicine & Molecular Imaging, 2025, v. 52, n. 5, p. 1751, doi. 10.1007/s00259-024-07022-z
- By:
- Publication type:
- Article
Exploring geriatric assessment‐driven rehabilitation referral patterns and its influence on functional outcomes and survival in older adults with advanced cancer.
- Published in:
- Journal of the American Geriatrics Society, 2025, v. 73, n. 1, p. 136, doi. 10.1111/jgs.19250
- By:
- Publication type:
- Article
Population pharmacokinetics and exposure–response relationships of dostarlimab in primary advanced or recurrent endometrial cancer in part 1 of RUBY.
- Published in:
- British Journal of Clinical Pharmacology, 2025, v. 91, n. 3, p. 841, doi. 10.1111/bcp.16325
- By:
- Publication type:
- Article
Comprehensive population pharmacokinetic modelling of sugemalimab, an anti‐programmed death‐ligand 1 (PD‐L1) human monoclonal antibody, in patients with solid tumours or lymphomas across multiple Phase I–III studies.
- Published in:
- British Journal of Clinical Pharmacology, 2025, v. 91, n. 3, p. 748, doi. 10.1111/bcp.16276
- By:
- Publication type:
- Article
Assessing reagents and techniques for identifying RhCE variants in routine serological testing.
- Published in:
- Vox Sanguinis, 2025, v. 120, n. 3, p. 301, doi. 10.1111/vox.13792
- By:
- Publication type:
- Article
Incidence and predictors of clinical failure after early treatment for mild‐to‐moderate COVID‐19 in high‐risk individuals: A multicentric cohort study.
- Published in:
- Journal of Internal Medicine, 2025, v. 297, n. 3, p. 328, doi. 10.1111/joim.20030
- By:
- Publication type:
- Article
Managing acute COVID-19 in immunocompromised pediatric patients.
- Published in:
- Expert Review of Clinical Immunology, 2024, v. 20, n. 4, p. 349, doi. 10.1080/1744666X.2023.2295982
- By:
- Publication type:
- Article
Teplizumab: promises and challenges of a recently approved monoclonal antibody for the prevention of type 1 diabetes or preservation of residual beta cell function.
- Published in:
- Expert Review of Clinical Immunology, 2024, v. 20, n. 2, p. 185, doi. 10.1080/1744666X.2023.2281990
- By:
- Publication type:
- Article
Bimekizumab for the treatment of psoriatic arthritis.
- Published in:
- Expert Review of Clinical Immunology, 2024, v. 20, n. 2, p. 155, doi. 10.1080/1744666X.2023.2277266
- By:
- Publication type:
- Article
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus.
- Published in:
- Expert Review of Clinical Immunology, 2024, v. 20, n. 1, p. 21, doi. 10.1080/1744666X.2023.2268284
- By:
- Publication type:
- Article
Pharmacokinetics of the Monoclonal Antibody, Sotrovimab, in Healthy Participants Following IM Administration at Different Injection Sites.
- Published in:
- Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 3, p. 759, doi. 10.1002/cpt.3515
- By:
- Publication type:
- Article
Impact of Chronic Inflammatory Diseases on Clinical Pharmacokinetics of Antibody‐Based Therapeutic Proteins.
- Published in:
- Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 3, p. 646, doi. 10.1002/cpt.3513
- By:
- Publication type:
- Article
Semimechanistic Population PK/PD Modeling of Axatilimab in Healthy Participants and Patients With Solid Tumors or Chronic Graft‐Versus‐Host Disease.
- Published in:
- Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 3, p. 704, doi. 10.1002/cpt.3503
- By:
- Publication type:
- Article
Model‐Informed Drug Development‐Based Approval of Intravenous Secukinumab for the Treatment of Adult Patients with Active Psoriatic Arthritis, Active Ankylosing Spondylitis, and Active Non‐Radiographic Axial Spondyloarthritis.
- Published in:
- Clinical Pharmacology & Therapeutics, 2025, v. 117, n. 2, p. 475, doi. 10.1002/cpt.3464
- By:
- Publication type:
- Article
Real‐Practice Analysis of Potential Antibiotic Interactions in Patients Treated With Immune Checkpoint Inhibitors: An Observational Study From an Italian Referral Cancer Center.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2025, v. 2025, p. 1, doi. 10.1155/jcpt/5572209
- By:
- Publication type:
- Article
Analysis of Predictors of Adverse Events and Mortality Risk Associated With IL‐6 Inhibitors: A Pharmacovigilance Study Using the FDA Adverse Event Reporting System Database.
- Published in:
- Journal of Clinical Pharmacy & Therapeutics, 2025, v. 2025, p. 1, doi. 10.1155/jcpt/5520102
- By:
- Publication type:
- Article
A Retrospective Study to Investigate Safety of Receiving Interleukin‐17 Monoclonal Antibody for Psoriasis Patients With Hepatitis B Virus.
- Published in:
- Dermatologic Therapy, 2025, v. 2025, p. 1, doi. 10.1155/dth/8942831
- By:
- Publication type:
- Article
Current and emerging PCSK9‐directed therapies to reduce LDL‐C and ASCVD risk: A state‐of‐the‐art review.
- Published in:
- Pharmacotherapy, 2025, v. 45, n. 1, p. 54, doi. 10.1002/phar.4635
- By:
- Publication type:
- Article
Experimentation of Heterocycles (2013‐22) as Potent Pharmacophores in Drug Design of Multiple Sclerosis.
- Published in:
- Drug Development Research, 2025, v. 86, n. 1, p. 1, doi. 10.1002/ddr.70059
- By:
- Publication type:
- Article
Lecanemab: The advent of biologicals in Alzheimer's disease, affordability, and clinical relevance.
- Published in:
- Journal of Applied Pharmaceutical Science, 2025, v. 15, n. 3, p. 30, doi. 10.7324/JAPS.2025.204843
- By:
- Publication type:
- Article
Expert Consensus on Surgical Management of Primary Diffuse Type 2‐Dominant Chronic Rhinosinusitis.
- Published in:
- International Forum of Allergy & Rhinology, 2025, v. 15, n. 3, p. 303, doi. 10.1002/alr.23538
- By:
- Publication type:
- Article
Physiology‐based pharmacokinetic model with relative transcriptomics to evaluate tissue distribution and receptor occupancy of anifrolumab.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 1, p. 105, doi. 10.1002/psp4.13245
- By:
- Publication type:
- Article
A model‐based approach using GSK3772847, an anti‐interleukin‐33 receptor monoclonal antibody, as a showcase to predict SC administration PK and free target dynamics based on PK and total target measurements after IV administration.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 1, p. 17, doi. 10.1002/psp4.13234
- By:
- Publication type:
- Article
Establishment of an ELISA‐based in vitro test system to quantify the major honey bee venom allergen Api m 10 in crude bee venoms and therapy allergen products.
- Published in:
- Allergy, 2025, v. 80, n. 3, p. 861, doi. 10.1111/all.16313
- By:
- Publication type:
- Article
Different Treatment Outcomes of Multiple Sclerosis Patients Receiving Ocrelizumab or Ofatumumab.
- Published in:
- Annals of Neurology, 2025, v. 97, n. 3, p. 583, doi. 10.1002/ana.27143
- By:
- Publication type:
- Article
Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: Results From a Randomized, Placebo‐Controlled Phase 3 Study.
- Published in:
- Arthritis & Rheumatology, 2025, v. 77, n. 2, p. 171, doi. 10.1002/art.42997
- By:
- Publication type:
- Article
Efficacy and Safety of Intravenous Secukinumab in Patients With Active Axial Spondyloarthritis: Results From a Randomized, Placebo‐Controlled, Phase 3 Study.
- Published in:
- Arthritis & Rheumatology, 2025, v. 77, n. 2, p. 163, doi. 10.1002/art.42993
- By:
- Publication type:
- Article
Emapalumab Treatment in Patients With Rheumatologic Disease–Associated Hemophagocytic Lymphohistiocytosis in the United States: A Retrospective Medical Chart Review Study.
- Published in:
- Arthritis & Rheumatology, 2025, v. 77, n. 2, p. 226, doi. 10.1002/art.42985
- By:
- Publication type:
- Article
Antigen Specificity: A Fluctuating Aspect in the Development of Clinical Antibodies?
- Published in:
- APMIS, 2025, v. 133, n. 1, p. 1, doi. 10.1111/apm.13515
- By:
- Publication type:
- Article
A minimal physiologically‐based pharmacokinetic modeling platform to predict intratumor exposure and receptor occupancy of an anti‐LAG‐3 monoclonal antibody.
- Published in:
- CPT: Pharmacometrics & Systems Pharmacology, 2025, v. 14, n. 3, p. 460, doi. 10.1002/psp4.13285
- By:
- Publication type:
- Article
Inhibition of FcRn with rozanolixizumab in adults with immune thrombocytopenia: Two randomised, double‐blind, placebo‐controlled phase 3 studies and their open‐label extension.
- Published in:
- British Journal of Haematology, 2025, v. 206, n. 2, p. 675, doi. 10.1111/bjh.19858
- By:
- Publication type:
- Article